大幸薬品 will transition from the Prime Market to the Standard Market with the approval of the Tokyo Stock Exchange. The transition will take effect on 2 November 2025, and the improvement plan to meet the listing maintenance criteria will be withdrawn. Reported by The Nikkei.
大幸薬品 announced on the 26th that it had received approval from the Tokyo Stock Exchange to change its market segment from the Prime Market to the Standard Market. The transition will take effect on 2 November, and the company had applied for the change in August.
The market capitalization of tradable shares was ¥9 billion as of the end of December 2026, below the Prime Market listing maintenance criterion of ¥10 billion. Following the approval, the company withdrew its improvement plan aimed at meeting the listing maintenance criteria.
For the fiscal year ending December 2026, the company forecasts consolidated revenue of ¥7.2 billion, up 12% year on year, and net profit of ¥550 million, down 40%.